FIGURE 1.

Waterfall plot of responses (n = 15 patients treated; (14 patients are shown; one patient [ID#9, Table 3]) was not evaluable because did not receive the full course of therapy due to infusion reaction to the first avelumab dose and withdrew consent during course 2; patient ID#15 had evaluable, but not measurable disease that was considered stable as best response). PFS, progression‐free survival; *Patient who received prior checkpoint inhibitor